Stem Cell Research- Dry AMD
Research at the University of California, reported in the journal Lancet, has demonstrated that stem cell therapy for AMD could be safe in the short term. The very small trial (2 patients) could pave the way for larger trials.
The person with dry AMD was in the end stage of the disease, experiencing loss of central vision. The participant received immunosuppressive treatment the week before transplant and an additional 12 weeks after. Stem cells were injected into one eye only. There was no excessive or abnormal growth of the transplanted cells. The participant experienced functional vision improvement.